BeiGene Announces The Phase 3 RATIONALE 315 Trial Met Primary Endpoints Of Major Pathological Response Rate And Event-Free Survival For Tislelizumab Plus Chemotherapy In Patients With Resectable Non-Small Cell Lung Cancer
Portfolio Pulse from Benzinga Newsdesk
BeiGene announced that its Phase 3 RATIONALE 315 trial met primary endpoints for tislelizumab plus chemotherapy in patients with resectable non-small cell lung cancer. The data showed 56.2% of patients achieved major pathological response, versus 15.0% with neoadjuvant chemotherapy alone. Also, 40.7% of patients achieved the key secondary endpoint of pathological complete response, compared to 5.7% with neoadjuvant chemotherapy alone.
October 17, 2023 | 8:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BeiGene's successful Phase 3 trial results for tislelizumab plus chemotherapy could potentially boost its stock in the short term.
Positive clinical trial results often lead to increased investor confidence, potentially leading to a rise in the company's stock price. The successful results of BeiGene's Phase 3 RATIONALE 315 trial for tislelizumab plus chemotherapy in NSCLC patients could therefore have a positive impact on its stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100